The Gross Law Firm Notifies Cytokinetics, Incorporated Investors of a Class Action Lawsuit and Upcoming Deadline - CYTK

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated regarding a class action lawsuit related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant financial losses for investors [1]. Group 1: Allegations and Timeline - The class period for the allegations is from December 27, 2023, to May 6, 2025 [1]. - Defendants allegedly made materially false statements about the expected FDA approval timeline for aficamten, claiming it would be approved in the second half of 2025 based on a September 26, 2025 PDUFA date [1]. - The company failed to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [1]. Group 2: Impact on Shareholders - On May 6, 2025, it was revealed during an earnings call that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [1]. - As a result of these misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was disclosed [1]. Group 3: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by November 17, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2].